Ensol Biosciences (XKRX:140610) Total Liabilities : ₩29,768 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Total Liabilities?

Ensol Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 was ₩29,768 Mil.

Ensol Biosciences's quarterly Total Liabilities declined from Dec. 2022 (₩18,934.14 Mil) to Dec. 2023 (₩14,846.82 Mil) but then increased from Dec. 2023 (₩14,846.82 Mil) to Dec. 2024 (₩29,768.22 Mil).

Ensol Biosciences's annual Total Liabilities declined from Dec. 2022 (₩18,934.14 Mil) to Dec. 2023 (₩14,846.82 Mil) but then increased from Dec. 2023 (₩14,846.82 Mil) to Dec. 2024 (₩29,768.22 Mil).

Ensol Biosciences Total Liabilities Historical Data

The historical data trend for Ensol Biosciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Total Liabilities Chart

Ensol Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

15,483.85

17,162.86

18,934.14

14,846.82

29,768.22

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23	Dec24
Total Liabilities	Get a 7-Day Free Trial						15,483.85	17,162.86	18,934.14	14,846.82	29,768.22

Ensol Biosciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Ensol Biosciences's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27497.368	+	(154.699	+	-4.5474735088646E-13
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2116.157	+	0)
	=	29,768

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	7554.726	-	-22213.498
	=	29,768

Ensol Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	27497.368	+	(154.699	+	-4.5474735088646E-13
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	2116.157	+	0)
	=	29,768

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	7554.726	-	-22213.498
	=	29,768

Ensol Biosciences Total Liabilities Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines